HC Wainwright Boosts Earnings Estimates for Pharming Group

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Equities researchers at HC Wainwright upped their FY2027 earnings per share estimates for Pharming Group in a report released on Wednesday, September 30th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of $0.54 per share for the year, up from their previous estimate of $0.50. HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.22 per share.

A number of other brokerages have also weighed in on PHAR. Canaccord Genuity Group set a $38.00 price target on shares of Pharming Group in a research note on Wednesday, September 23rd. Zacks Research downgraded Pharming Group from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Weiss Ratings reiterated a “sell (d)” rating on shares of Pharming Group in a research report on Friday, August 7th. Finally, Oppenheimer restated an “outperform” rating on shares of Pharming Group in a report on Thursday, July 30th. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $38.67.

Pharming Group Stock Performance

PHAR stock opened at $9.75 on Friday. The company has a 50-day simple moving average of $11.15 and a 200 day simple moving average of $13.28. The company has a market capitalization of $690.11 million, a P/E ratio of 81.25 and a beta of -0.05. The company has a quick ratio of 2.31, a current ratio of 3.01 and a debt-to-equity ratio of 0.34. Pharming Group has a fifty-two week low of $9.62 and a fifty-two week high of $21.34.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, July 30th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP acquired a new stake in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group makes up about 6.0% of MAC Alpha Capital Management LP’s holdings, making the stock its 2nd biggest position. MAC Alpha Capital Management LP owned 3.03% of Pharming Group at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V. is a global biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and conditions with significant unmet medical needs, using biotechnology and protein-replacement approaches.

Pharming’s commercial products include Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral therapy for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency disorder.